---
title: "Fresenius keeps 2026 outlook unchanged after German health insurance contribution law passed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292438444.md"
description: "Fresenius maintains its 2026 outlook unchanged following the passage of Germany's GKV contribution rate stabilization law. The company expects the legislation to support annual growth in hospital reimbursement rates, noting the final version is more favorable than the initial draft. Helios revenue targets remain intact, including a 10%-12% EBIT margin goal under the group’s financial framework."
datetime: "2026-07-13T05:06:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292438444.md)
  - [en](https://longbridge.com/en/news/292438444.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292438444.md)
---

# Fresenius keeps 2026 outlook unchanged after German health insurance contribution law passed

-   Fresenius said its 2026 outlook is unchanged following German passage of the GKV contribution rate stabilization law on July 10. \* It expects the law to support annual growth in hospital reimbursement rates, calling the final version more favorable than the cabinet draft. \* Targets for Helios revenue remain intact, including the 10%-12% EBIT margin goal under the group’s financial framework. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [FSNUY.US](https://longbridge.com/en/quote/FSNUY.US.md)
- [FRE.DE](https://longbridge.com/en/quote/FRE.DE.md)

## Related News & Research

- [Fresenius Kabi vedolizumab biosimilar PB016 accepted for FDA, EMA review](https://longbridge.com/en/news/294465104.md)
- [Fresenius names Thomas Thestrup head of new Ventures unit](https://longbridge.com/en/news/293578816.md)
- [Fresenius establishes venture fund of more than €200 million to drive healthcare innovation | FSNUY Stock News](https://longbridge.com/en/news/293588612.md)
- [Dolfines announces availability of H1 2026 revenue report](https://longbridge.com/en/news/294233994.md)
- [Deutsche Bank  Reaffirms Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)](https://longbridge.com/en/news/293183874.md)